Genetic abnormalities in plasma DNA of patients with lung cancer and other respiratory diseases
Genetic abnormalities in plasma DNA of patients with lung cancer and other respiratory diseases
复制标题
肺癌和其他呼吸系统疾病患者血浆DNA的遗传异常
DOI：
10.1002/ijc.20156
复制
发表时间：
2004
影响因子：
6.4
通讯作者：
P. Woll
中科院分区：
文献类型：
--
作者：
Sarah Khan;J. Coulson;P. Woll
检测血浆 DNA 中与肿瘤相关的基因改变已被提议作为一种简单的方法，用于早期诊断肺癌和识别可能被纳入筛查或化学预防计划的肺癌高风险个体。为了评估这种方法的实用性，我们在肺癌人群中筛选了一组 16 种血浆 DNA 标记物，以识别那些基因改变率最高的人群。然后将这些样本用于研究 206 名患有肺癌和其他呼吸道疾病的医院门诊患者的血浆 DNA。从医院门诊患者采集的血液样本中分离出血浆和淋巴细胞 DNA。采用覆盖染色体区域3p、8p、9p、13q和17p的16个微卫星标记，使用来自32名肺癌患者的DNA进行聚合酶链反应。选择最常受影响的 3 种标记物用于一项对 86 名肺癌患者和 120 名其他呼吸系统疾病患者进行的大型研究。在试点研究中，3对引物（D3S1300、D3S1560、D8S201）共同检测了 60% 肺癌患者血浆 DNA 的遗传改变。在更大规模的研究中，在肺癌患者中观察到两个标记物 D3S1560 和 D8S201 的基因改变率显着高于其他呼吸系统疾病患者。肺癌患者的总体基因改变率为 69%，其他呼吸系统疾病患者的总体基因改变率为 42% (p < 0.001)。在大型研究中，通过分析血浆和淋巴细胞 DNA 来检测肺癌典型的基因改变是可能的。我们在肺癌患者中发现的基因改变率与其他研究相当。尽管肺癌患者的基因改变率显着高于呼吸系统疾病患者，但在该人群中没有良好的阳性预测价值。需要进行纵向研究来确定非癌症患者血浆 DNA 的遗传变化是否表明晚期肺癌的高风险。 © 2004 Wiley-Liss, Inc.
The detection of tumour‐associated genetic alterations in plasma DNA has been proposed as a simple method for the early diagnosis of lung cancer and for identifying individuals at high risk of lung cancer who might be included in screening or chemoprevention programmes. To evaluate the practicality of this approach, we screened a panel of 16 plasma DNA markers in a lung cancer population to identify those with the highest genetic alteration rate. These were then used to study plasma DNA in 206 hospital outpatients with lung cancer and other respiratory diseases. Plasma and lymphocyte DNA were isolated from blood samples collected from hospital outpatients. Polymerase chain reaction was carried out with 16 microsatellite markers covering chromosomal regions 3p, 8p, 9p, 13q and 17p, using DNA from 32 lung cancer patients. The 3 markers most commonly affected were selected for use in a larger study of 86 lung cancer patients and 120 patients with other respiratory diseases. In the pilot study, 3 primer pairs (D3S1300, D3S1560, D8S201) together detected genetic alterations in plasma DNA in 60% of lung cancer patients. In the larger study, significantly higher genetic alteration rates were observed in lung cancer patients than in patients with other respiratory diseases for the two markers D3S1560 and D8S201. The overall genetic alteration rate was 69% in the lung cancer patients and 42% in the patients with other respiratory diseases (p < 0.001). Analysis of plasma and lymphocyte DNA to detect genetic alterations typical of lung cancer is possible in large studies. The genetic alteration rate we found in lung cancer patients was comparable with other studies. Although the genetic alteration rate was significantly higher in the lung cancer than the respiratory disease patients, it did not have good positive predictive value in this population. Longitudinal studies are required to determine whether genetic changes in plasma DNA of non‐cancer patients indicate a high risk of later lung cancer. © 2004 Wiley‐Liss, Inc.
DOI：
10.1016/s0169-5002(97)80271-1
发表时间：
1997-08
期刊：
Journal of the National Cancer Institute
影响因子：
--
作者：
I. Wistuba;S. Lam;C. Behrens;A. Virmani;K. Fong;J. Leriche;J. Samet;S. Srivastava;J. Minna;A. Gazdar
通讯作者：
I. Wistuba;S. Lam;C. Behrens;A. Virmani;K. Fong;J. Leriche;J. Samet;S. Srivastava;J. Minna;A. Gazdar
影响因子：
11.2
作者：
Montserrat Sanchez-Cespedes;P. Decker;K. Doffek;M. Esteller;W. Westra;Enas A. Alawi;James G. Herman-James-G.-Herm
通讯作者：
Montserrat Sanchez-Cespedes;P. Decker;K. Doffek;M. Esteller;W. Westra;Enas A. Alawi;James G. Herman-James-G.-Herm